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The requirement of high doses of interferon (IFN) during therapy severely restrict its application. Thus a 
model using an Epstein-Barr virus (EBV) membrane antigen (MA) specific monoclonal antibody (MAb) 
was developed to assess the feasibility of coupling minimal amounts of IFN to a MAb and specifically de- 
livering the IFN to the target cells. Coupled IFN was first shown to retain fully both its anti-viral and anti- 
proliferative properties when tested on human tumor cell lines QIMR-WIL (EBV-MA+) and the U-266 
(EBV-MA-). A series of in vitro pulsing experiments demonstrated the specific targeting of both the anti- 
viral and anti-proliferative properties of IFN to the EBV-MA+ QIMR-WIL cells and not EBV-MA- cell 
lines. 
Recombinant interferon ~onoclo~af antibody Thrgeting Growth ~~hibjtio~ 
1. INTRODUCTION 
The anti-viral and anti-tumour efficacy of both 
natural and recombinant interferons (nIFN, rIFN) 
currently available for clinical application has so 
far been disappointing [l-3]. This may in part be 
explained by the short half-life of IFN prepara- 
tions, their lack of target cell specificity, rapid 
degradation and dilution effects in vivo. These all 
necessitate increased administration of IFN 
resulting in severe side effects [1,3,4]. An approach 
aimed at stabilising IFN or more specifically 
delivering the IFN to given target cells might help 
to overcome these problems. 
maintains protein activity and prevents the forma- 
tion of intramolecular cross-links or homo-poly- 
merization 161. The targeting efficiency, anti-viral 
and anti-proliferative activities of the IFN-MAb 
conjugate were tested on an EBV infected human 
tumor cell line QIMR-WIL [7] which expresses the 
EBV-MA and control cells negative for EBV-MA. 
2. MATERIALS AND METHODS 
Here we report our initial experiments 
demonstrating the feasibility of specifically 
targeting IFNs by coupling them to monoclonal 
antibodies (MAbs) specific for an Epstein-Barr 
virus (EBV) membrane antigen (MA) [5]. For this 
purpose the bifunctional reagent N-succinimidyl- 
3-(2-pyrridyl(dithio)propionate (SPDP) was used 
because of its very mild cross-linking ability which 
MAb 53880.17 (y2bx) specific for EBV-MA 
p 340 was obtained and purified as in [5]. Human 
recombinant IFN (u/B, used throughout these ex- 
periments, was kindly provided by Dr F. Meyer, 
Base1 and affinity purified as in IS]. 
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Human IFN was coupled to MAb 53580.17 ac- 
cording to [7]. Briefly, to 1 ml of a stirred 
phosphate-buffered saline (PBS) solution, pH 7.2, 
containing 6 mg MAb or 100 ng IFN, 8 ~1 of a 
20 mM solution of SPDP was added for 20 min at 
room temperature (RT). The IFN was then dia- 
lysed for 16 h against PBS. The MAb was dialysed 
against sodium acetate buffer, pH 4.5, followed by 
incubation with 25 mM dithiothreitol for 15 min 
and further dialysis against PBS. Derivatized IFN 
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and thiolated MAb were then mixed and incubated 
for 2 h at RT and finally overnight at 4°C. The 
IFN-MAb conjugate was then passed through a 
20 ml Sephadex G-200 (Pharmacia) column to 
remove any uncoupled IFN. 
The activity of IFN was determined in a stan- 
dard bioassay [9] by measuring the inhibition of 
Mengo virus challenge (800 PFU/well) on human 
Hep 2 cells (3 x 104 ce~s/microtiter well} using an 
international IFNa standard (B69/19, Natl. Inst. 
Biol. Stds., UK) as a reference value. 
The anti-viral activity of IFN-MAb conjugates 
was tested on EBV-MA+ QIMR-WIL and EBV- 
MA- U266 [lo] (both 3 x l@/well in 100~1). 
Target cells were incubated in RPM1 plus 10% 
fetal calf serum (FCS) in microtiter plates (Falcon) 
with either IFN, MAb, IFN-MAb conjugates, 
MAb + IFN mixtures or medium alone. After 
overnight incubation Mengo virus (800 PFU/well 
for both target lines) was added to a test plate or 
the equivalent amount of medium to a second con- 
trol plate. After a further 48 h incubation, cells 
were tested for viability using fluorescein diacetate 
(FDA). The anti-proliferative activity of IFN-MAb 
conjugates was assessed in a a similar way, but 
omitting viral challenge. Instead cells were pulsed 
for 2 h on day 3 of culture with 0.2&i 
[3H]TdR/well, harvested (Titertek) and counted. 
Pulsing experiments were performed aimed at 
demonstrating the specific targeting of both anti- 
viral and anti-proliferative activities of IFN by 
MAb. Target cells, EBV-MA+, QIMR-WIL [7], 
EBV-MA- cell lines; Hep2 [l 11, Namalwa [ 121, 
U-266 [IO] and ARH-77 [13] were incubated as 
above but for 15 min at 4°C with either medium, 
uncoupled IFN, IFN-MAb conjugate, IFN plus 
MAb mixture, then washed 3 times in a large ex- 
cess of balanced salt solution and finally 
distributed at 5 x 104 cells in 100 ~1 into microtiter 
wells per test and per control plate for each cell 
line. Anti-viral and anti-proliferative activities 
were then assessed as above. 
Table 1 
Antibody coupled IFN maintains its anti-viral and anti-proliferative activities 
-. ~ ~~ 
Cells IFN olo protection from lysis 13H]TdR incor~ration 
treated dose 
with (IU/ml) QIMR-WIL U-266 QIMR-WIL cells U-266 cells 
cells cells 
cpm x 10e3 % cpm x lo-’ % 
inhibition inhibition 
Medium 0 4 20 36.5 0 14 0 
IFN alone 1 58 68 16.8 27 10.6 24 
10 95 100 13.4 34 6.7 52 
100 NT NT 10.1 45 5.3 62 
I~-MAP 1 50 69 5.3 86 14.9 22 
conjugate 10 100 100 2.8 92 10.2 32 
100 NT NT 0.4 99 5.1 64 
MAb alone 0 4 19 8 6 
Target cells QIMR-WIL and U-266 were incubated for 2-3 days in the presence of different concentrations of IFN-MAb 
conjugate, IFN plus MAb mixture, IFN or MA\, alone. The anti-viral and anti-proliferative activities were determined 
as described in section 2. The percent protection from viral challenge was calculated from the ceil number found in the 
absence of virus (= 100% growth) for each IFN dose applied. This reference value was required for each IFN dose, 
because it was not possible to assay the anti-viral activity without simultaneously invoking IFN induced growth 
inhibition. Throughout this study all assays were performed in duplicate and all counts were conducted in a double blind 
manner. The percent inhibition of [3H]TdR incorporation was determined from the controls representing maximal (i.e., 
100%) incorporation from which the percent inhibition caused by the various IFN doses was calculated 
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3. RESULTS dicating a specific targeting effect due to MAb. 
Effective coupling of IFN to MAb was 
reproducibly found to be 85% as determined by 
IFN bioassay, protein measurements, and specific 
antibody determinations (cell binding radio- 
immunoassay). Radiolabelled IFN experiments 
demonstrated that Sephadex chromatography (see 
section 2) successfully separated uncoupled from 
coupled IFN. The resulting IFN-MAb ratio varied 
between low3 and 10e4. 
Table 1 demonstrates the maintenance of the 
anti-viral and anti-proliferative activities of the 
IFN-MAb conjugate on QIMR-WIL and U-266 
cells. The conjugate conferred the same degree of 
viral protection compared to the uncoupled IFN: 
1 IU/ml of uncoupled IFN or IFN-MAb conjugate 
protected 50-60% of the cells while 10 or more 
III/ml IFN resulted in complete protection from 
viral lysis. Similarly the anti-proliferative effect of 
IFN-MAb conjugate compared to uncoupled IFN 
was maintained on QIMR-WIL and U266 cells 
(table 1). Further, an enhanced inhibition was 
observed with the relevant conjugate on QIMR- 
WIL cells in comparison to the uncoupled IFN in- 
Short-term pulsing experiments then demon- 
strated the specific targeting in vitro of IFN-MAb 
conjugate to the relevant EBV-MA” QIMR-WIL 
cells. Full protection from viral challenge was 
found only in QIMR-WIL cells when treated with 
IFN-MAb conjugate (table 2). Uncoupled IFN or 
MAb + IFN mixture did not confer a significant 
degree of protection in either QIMR-WIL or U266 
cells (not shown). A dramatic growth inhibition 
(96% at 500 IU/ml IFN-MAb conjugate) was only 
demonstrated when the specific MAb targeted IFN 
to the EBV-MA” QIMR-WIL cells (table 3). In 
contrast no IFN-MAb conjugate mediated growth 
inhibition could be demonstrated on EBV-MA- 
control cells, i.e., Hep 2, Namalwa, U266 and 
ARH-77 (table 3). In addition, viability counts 
(FDA) on QIMR-WIL and U266 cells indicated 
that approx. 50% of the QIMR-WIL cells and not 
U266 were killed by the targeted conjugate while 
the remaining cells were arrested in growth for the 
duration of the culture (3-4 days). Furthermore, 
similar results were found when natural IFNa was 
conjugated to EBV-MA+ MAbs using the same 
methods and assay systems (not shown). 
Table 2 





IFN dose Number of % prot~tion Number of % protection 
(IU/ml) viable QIMR-WIL from lysis viable U-266 from lysis 
cells ( x 10m3) cells (x 10e3) 
0 60 6.6 80 20 
IFN alone 5 100 20 60 24 
500 150 30 50 20 
IFN-MAb 5 460 63 25 
conjugate 500 490 
u 92 
98 65 26 
MAb alone 0 80 I6 30 12 
Target cells were incubated in 0.2 ml RPMI/IO~o FCS and pulsed for I5 min at 4°C with varying dilutions of IFNs 
followed by copious washing. After viral challenge the viable cells remaining were counted using FDA. Results are 
expressed in terms of percent protection from viral lysis in comparison to the virus free control plate (i.e., no viral 
challenge = 100% protection) for each IFN dose. Cell numbers in the absence of virus were 900 x 103/ml for QIMR- 
WIL and 400 x 103/mI for U-266 cells. Note that Mengo virus was only capable of maximally lysing 80% of non- 
protected U-266 cells and this is seen as a 20% background protection level 
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Table 3 





IFN Target cells/13H]TdR incorporation 
dose 
(IU/ml) QIMR-WIL HEP 2 NAMALWA U-266 ARH-77 
cpm x % inh. cpm x % inh. cpm x 8’0 inh. cpm x % inh. cpm x % inh. 
10-s 10-J 1O-3 1O-3 10-r 
Medium 0 45-49 0 
IFN alone 5 46-52 0 
50 48-51 0 
500 41-48 6 
3-5 0 62-68 0 5-7 0 52-57 0 
NT NT 5-7 0 53-56 0 
NT NT NT NT 




NT NT 5-6 17 47-56 6 
NT NT NT NT 
3.5-5.2 0 65-67 2 4-7 17 50-56 0 
IFN+MAb 5 40-52 2 NT NT NT NT 
mixture 50 44-51 0 NT NT NT NT 
500 45-50 0 NT NT NT NT 
MAb alone 0 44-45 4 3.1-3.5 12 67-68 0 6-7 0 56-57 0 
Target cells were pulsed as for table 2 but without viral challenge. Instead viable counts were performed on day 3 and 
the cells pulsed for 2 h with [3H]TdR as described in section 2. Results are expressed in terms of percent inhibition (olo 
inh.) of the maximal control values, i.e., in the absence of IFN 
4. DISCUSSION 
Our results clearly remonstrate the maintenance 
of IFN’s biological activities on coupling to MAb 
also shown in [14] but more importantly illustrate 
a potential for specifically delivering these proper- 
ties to a desired target cell population depending 
on the specificity of the carrier molecule, i.e., 
MAb. In this case IFN-MAb conjugate was 
specifically targeted to the EBV-MA+ cell line 
QIMR-WIL under very short pulsing conditions 
(15 min) at low temperature (4”(Z), to avoid bind- 
ing of IFN to its receptor and was able to provide 
full protection from viral challenge and inhibit cell 
growth. Viable counts indicated a direct cytotoxic 
effect of the IFN-MAb conjugate on QIMR-WIL 
cells in contrast o uncoupled IFN which even after 
very long incubation periods could only arrest but 
not kill these cells. Further the surprisingly low 
molar ratio of IFN to MAb ( 10m4) did not limit the 
32 
targeting of IFNs potent activities. These findings 
seem to indicate that once IFN is specifically 
delivered it affects other cells in the vicinity as well 
and/or it can be repeatedly used by several cells. 
The above observations and our recent data ob- 
tained by the use of radiolabelled IFN-MAb con- 
jugates 1151 lend hope to the potential application 
of extremely low doses of IFN in vivo thereby 
eliminating severe side effects and further impar- 
ting target cell specificity and thus localisation of 
therapeutic effects. 
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